Efficacy of Mazdutide for Treating PCOS

NCT06519656 · Recruiting

Last updated 2026-05-28

This clinical trial is testing whether the medication Mazdutide can help reduce high androgen levels in women with polycystic ovary syndrome (PCOS).

Status Recruiting Currently enrolling participants.

Phase Phase1, Phase2

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 50 people Planned (estimated).

Who can join Ages 18–40 · female only

Timeline Started 2024-10 · est. completion 2026-06

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT06519656 ↗

Description as written by the study sponsor.

The goal of this clinical trial is to learn the efficacy of Mazdutide in treating obese female adults diagnosed with polycystic ovary syndrome (PCOS). The main question it aims to answer is: Does Mazdutide lower the free androgen index (FAI) in obese female adults with PCOS? Participants will take Mazdutide once every week for 24 weeks and visit the clinic once every 4 weeks for checkups and tests.

Treatments tested

Mazdutide also known as GLP-1R and GCGR dual agonist Drug

In the initial 4 weeks, the subjects are given Mazdutide 2mg once weekly. If well tolerated, the dosage is increased to 4mg once weekly for another 4 weeks. If still well tolerated, the dosage is further increased to 6mg once weekly and maintained for the ensuing 16 weeks.

Main thing measured	Free Androgen Index (FAI)
Sponsor	Shanghai Zhongshan Hospital
Conditions studied	Polycystic Ovary Syndrome
GLP-1 drugs	mazdutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06519656 ↗